Page 173 - Screening for Cervical Cancer: Systematic Evidence Review
P. 173
Chapter III. Results
Neg. LR 0.43 0.50 0.43 0.30 0.73 0.56 0.22 0.40 0.40 0.30
Performance of Screening HPV* Testing for Detection of Low-grade or More Severe Abnormalities
Pos. LR 19.4 3.4 12.5 1.62 1.83 1.82 5.42 3.4 3.5 7.7
PPV ll NPV ll 98.4 46.0 98.3 11.3 98.6 31.0 86.5 45.6 89.2 23.3 83.5 39.3 98.3 28.4 93.4 36.7 93.6 35.7 98.5 29.2
Spec Prev § 4.22 96.7 3.66 81.7 3.46 95.1 34.1 47.0 14.3 75.3 26.2 64.9 7.6 84.5 14.7 80.1 13.8 81.2 5.1 90.5
False Pos. 95 227 80 87 46 555 197 965 878 277
True Neg. 2767 1011 1564 77 140 1024 1072 3877 3800 2636
Sens 64.3 61.7 61.0 85.9 45.2 64.0 81.3 67.3 65.2 73.5 HIV, human immunodeficiency virus, where + indicates participants with HIV infection and should be indicates those without infection.
False Neg. 45 18 23 12 17 202 18 272 260 41
True Pos. 81 29 36 73 14 359 78 560 487 114
Total N 2988 1285 1703 249 217 2140 1365 5674 5425 3068 ¶ Pos LR and Neg LR, positive and negative likelihood ratio.
Test Method SHARP # I** HC II HC HC II (HIV+ ) HC II (HIV- ) HCII HC II HC II in populations with *HPV, human papilloma virus. ll PPV and NPV, positive and negative predictive value. Physician collected samples. # SHARP, SHARP detection system.
Table 9. Article Cuzick et al. 1999 21 Womack et al. 2000 63 Womack et al. 2000 62 Wright et al. 2000 64 Total all HC II HC II excluding HIV+ prevalence <10% § Prev, prevalence. Sens, sensitivity. Spec, specificity. **HC, hybrid capture.
72
